BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 22133721)

  • 21. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive value of PDL1 expression in breast cancer.
    Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F
    Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed cell death ligand 1 expression in osteosarcoma.
    Shen JK; Cote GM; Choy E; Yang P; Harmon D; Schwab J; Nielsen GP; Chebib I; Ferrone S; Wang X; Wang Y; Mankin H; Hornicek FJ; Duan Z
    Cancer Immunol Res; 2014 Jul; 2(7):690-698. PubMed ID: 24866169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
    Yokosuka T; Takamatsu M; Kobayashi-Imanishi W; Hashimoto-Tane A; Azuma M; Saito T
    J Exp Med; 2012 Jun; 209(6):1201-17. PubMed ID: 22641383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.
    Patsoukis N; Bardhan K; Chatterjee P; Sari D; Liu B; Bell LN; Karoly ED; Freeman GJ; Petkova V; Seth P; Li L; Boussiotis VA
    Nat Commun; 2015 Mar; 6():6692. PubMed ID: 25809635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
    Ray A; Das DS; Song Y; Richardson P; Munshi NC; Chauhan D; Anderson KC
    Leukemia; 2015 Jun; 29(6):1441-4. PubMed ID: 25634684
    [No Abstract]   [Full Text] [Related]  

  • 27. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
    D'Incecco A; Andreozzi M; Ludovini V; Rossi E; Capodanno A; Landi L; Tibaldi C; Minuti G; Salvini J; Coppi E; Chella A; Fontanini G; Filice ME; Tornillo L; Incensati RM; Sani S; Crinò L; Terracciano L; Cappuzzo F
    Br J Cancer; 2015 Jan; 112(1):95-102. PubMed ID: 25349974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
    Merelli B; Massi D; Cattaneo L; Mandalà M
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shp1 regulates T cell homeostasis by limiting IL-4 signals.
    Johnson DJ; Pao LI; Dhanji S; Murakami K; Ohashi PS; Neel BG
    J Exp Med; 2013 Jul; 210(7):1419-31. PubMed ID: 23797092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
    Ostrand-Rosenberg S; Horn LA; Haile ST
    J Immunol; 2014 Oct; 193(8):3835-41. PubMed ID: 25281753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
    Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A
    Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.
    Le Mercier I; Lines JL; Noelle RJ
    Front Immunol; 2015; 6():418. PubMed ID: 26347741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
    Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
    Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
    Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
    J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.
    Dulos J; Carven GJ; van Boxtel SJ; Evers S; Driessen-Engels LJ; Hobo W; Gorecka MA; de Haan AF; Mulders P; Punt CJ; Jacobs JF; Schalken JA; Oosterwijk E; van Eenennaam H; Boots AM
    J Immunother; 2012; 35(2):169-78. PubMed ID: 22306905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical blockade of PD1 and LAG3--potential mechanisms of action.
    Nguyen LT; Ohashi PS
    Nat Rev Immunol; 2015 Jan; 15(1):45-56. PubMed ID: 25534622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
    Herbst RS; Soria JC; Kowanetz M; Fine GD; Hamid O; Gordon MS; Sosman JA; McDermott DF; Powderly JD; Gettinger SN; Kohrt HE; Horn L; Lawrence DP; Rost S; Leabman M; Xiao Y; Mokatrin A; Koeppen H; Hegde PS; Mellman I; Chen DS; Hodi FS
    Nature; 2014 Nov; 515(7528):563-7. PubMed ID: 25428504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
    Atefi M; Avramis E; Lassen A; Wong DJ; Robert L; Foulad D; Cerniglia M; Titz B; Chodon T; Graeber TG; Comin-Anduix B; Ribas A
    Clin Cancer Res; 2014 Jul; 20(13):3446-57. PubMed ID: 24812408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
    Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.